VOLUME 17 - NUMBER 2 / April-June (Original Article)
Sara Olivia Ramos-Romero, Residente de 4.º año, Hospital de Oncología, CMN Siglo XXI, IMSS, Ciudad de México, México
Rubén Figueroa-Aragón, Médico adscrito al Centro Médico Nacional Siglo XXI, IMSS, Ciudad de México
Rodrigo Silva-Martínez, Médico Especialista en Cirugía Oncológica, Hospital de Oncología, CMN Siglo XXI, IMSS, Ciudad de México, México
Introduction: Laryngeal cancer is one of the most common head and neck neoplasms. Most cases are diagnosed at advanced stages. In clinical Stage III larynx cancer organ preservation protocols, chemoradiotherapy is the treatment of choice, with high local control and laryngectomy free survival rates in well selected patients. In our country, exploration of this results has not been made. Objetives: To retrospectively describe organ preservation, local control and morbidity after a two years follow-up. Materials and Methods: Clinical and electronic records of patients diagnosed with glottic laryngeal cancer Stage III T3NOMO treated with intensity-modulated radiation therapy (IMRT) concomitant with chemotherapy were reviewed in the period from January 2013 to December 2015. The study design was descriptive, observational, transversal and retrospective. Results: In the period between 2013 and 2015 at CMN SIGLO XXI Oncology Hospital, 266 patients with laryngeal cancer were treated; only 11 patients met the inclusion criteria for our study. After 2 years, locoregional control and organ preservation were 100%, no 3 or 4 grade morbidity was observed. Conclusion: In our study, the IMRT concomitant with chemotheraphy in glottic laryngeal cancer Stage III T3N0M0 offers 100% organ preservation, and locoregional control, with acceptable
morbidity at 2 years.
Keywords: Glottic laringeal cancer. Organ preservation. Locoregional control. Morbidity. IMRT technique.
